Andrew G Sokolow
Overview
Explore the profile of Andrew G Sokolow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wyatt M, Sokolow A, Brown R, Kaslow J, Tolle J, Weiner D, et al.
Pediatr Pulmonol
. 2024 Apr;
59(6):1747-1756.
PMID: 38558514
Objectives: In adults, an isolated low FEV pattern (an FEV below the lower limit of normal with a preserved FVC and FEV/FVC) has been associated with the risk of developing...
2.
Reasoner S, Bernard R, Waalkes A, Penewit K, Lewis J, Sokolow A, et al.
mBio
. 2024 Jan;
15(2):e0193523.
PMID: 38275294
The intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores the function of the pathogenic mutated CF...
3.
Reasoner S, Bernard R, Waalkes A, Penewit K, Lewis J, Sokolow A, et al.
medRxiv
. 2023 Aug;
PMID: 37645804
The intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores function of the pathogenic mutated CFTR channel....
4.
Saxena S, Doyle P, Baron C, Doyle T, Sokolow A
Am J Respir Crit Care Med
. 2023 Jan;
207(11):1533-1535.
PMID: 36662634
No abstract available.
5.
Reasoner S, Fazili I, Bernard R, Parnell J, Sokolow A, Thomsen K, et al.
J Cyst Fibros
. 2022 Dec;
22(5):884-887.
PMID: 36585317
Patients with CF (pwCF) have high antibiotic use and an altered intestinal microbiome, known risk factors for infection with Clostridioides difficile. However, in adults with CF, C. difficile infection (CDI)...
6.
Kaslow J, Sokolow A, Donnelly T, Buchowski M, Markham L, Burnette W, et al.
Pediatr Pulmonol
. 2022 Dec;
58(4):1034-1041.
PMID: 36571207
Background: Duchenne muscular dystrophy (DMD) is associated with progressive muscle weakness and respiratory decline. To date, studies have focused on respiratory decline and loss of ambulation as a metric of...
7.
Sokolow A, Stallings A, Kercsmar C, Harrington T, Jimenez-Truque N, Zhu Y, et al.
Pediatrics
. 2022 Mar;
149(4).
PMID: 35342923
Background And Objectives: Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged ≥5 years because of concerns for wheezing events. We evaluated...
8.
Kaslow J, Sokolow A, Donnelly T, Buchowski M, Damon B, Markham L, et al.
Neuromuscul Disord
. 2022 Mar;
32(5):390-398.
PMID: 35300894
Duchenne muscular dystrophy (DMD) is characterized by muscle deterioration and progressive weakness. As a result, patients with DMD have significant cardiopulmonary morbidity and mortality that worsens with age and loss...
9.
Kaslow J, Soslow J, Burnette W, Raucci F, Hills T, Ibach M, et al.
Respir Care
. 2021 Dec;
67(3):347-352.
PMID: 34876494
Background: Duchenne muscular dystrophy (DMD) is a devastating, progressive neuromuscular disease that results in cardiopulmonary failure and death. In 2018, the DMD Care Considerations guidelines were updated to improve the...
10.
Clegg J, Malloy K, Brown R, Grisso A, Sokolow A
J Cyst Fibros
. 2021 Aug;
21(3):549-550.
PMID: 34391678
No abstract available.